Actualités Xilio Therapeutics Inc - XLO | Actions NASDAQ

Outils de qualité professionnelle, pour des investisseurs individuels.

Statement of Changes in Beneficial Ownership (4)

FORM 4 ☐ Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b...

Statement of Changes in Beneficial Ownership (4)

FORM 4 ☐ Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b...

Statement of Changes in Beneficial Ownership (4)

FORM 4 ☐ Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b...

Current Report Filing (8-k)

0001840233false00018402332023-06-082023-06-08UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C...

Current Report Filing (8-k)

0001840233false00018402332023-05-252023-05-25UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C...

Xilio Therapeutics Announces Preliminary Clinical Data from Phase 1 Trial of XTX101, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, in Patients with Advanced Solid Tumors

Encouraging preliminary anti-tumor activity observed in a patient with PD-L1 negative advanced non-small cell...

Quarterly Report (10-q)

0001840233--12-312023Q1false0001840233srt:MaximumMemberxlo:StockIncentivePlan2021Member2021-10-012021-10-310001840233srt:MaximumMemberus-gaap:Emplo...

Current Report Filing (8-k)

0001840233false00018402332023-05-092023-05-09UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C...

Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2023 Financial Results

Initiated Phase 2 clinical trial for XTX202, a tumor-activated IL-2 Anticipate reporting preliminary Phase 1...

Additional Proxy Soliciting Materials (definitive) (defa14a)

UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549SCHEDULE 14AProxy...

Proxy Statement (definitive) (def 14a)

Table of ContentsUNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549SCHEDULE...

Statement of Ownership (sc 13g)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under...

Statement of Changes in Beneficial Ownership (4)

FORM 4 ☐ Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b...

Initial Statement of Beneficial Ownership (3)

FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549...

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Xilio Therapeutics Inc (XLO)

Outils de qualité professionnelle, pour des investisseurs individuels.

XLO Actualités

Statement of Changes in Beneficial Ownership (4)

Statement of Changes in Beneficial Ownership (4)

Statement of Changes in Beneficial Ownership (4)

Current Report Filing (8-k)

Current Report Filing (8-k)

Xilio Therapeutics Announces Preliminary Clinical Data from Phase 1 Trial of XTX101, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, in Patients with Advanced Solid Tumors

Quarterly Report (10-q)

Current Report Filing (8-k)

Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2023 Financial Results

Additional Proxy Soliciting Materials (definitive) (defa14a)

Proxy Statement (definitive) (def 14a)

Statement of Ownership (sc 13g)

Statement of Changes in Beneficial Ownership (4)

Initial Statement of Beneficial Ownership (3)

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Xilio Therapeutics Inc (XLO) Actualités

Xilio Therapeutics Inc (XLO)

Outils de qualité professionnelle, pour des investisseurs individuels.

XLO Actualités

Statement of Changes in Beneficial Ownership (4)

Statement of Changes in Beneficial Ownership (4)

Statement of Changes in Beneficial Ownership (4)

Current Report Filing (8-k)

Current Report Filing (8-k)

Xilio Therapeutics Announces Preliminary Clinical Data from Phase 1 Trial of XTX101, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, in Patients with Advanced Solid Tumors

Quarterly Report (10-q)

Current Report Filing (8-k)

Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2023 Financial Results

Additional Proxy Soliciting Materials (definitive) (defa14a)

Proxy Statement (definitive) (def 14a)

Statement of Ownership (sc 13g)

Statement of Changes in Beneficial Ownership (4)

Initial Statement of Beneficial Ownership (3)

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application